[Cost-utility of vaccination against chickenpox in children and against herpes zoster in elderly in Belgium]

Bilcke J, Marais C, Ogunjimi B, van Hoek AJ, Lejeune O, Callens M, Vancorenland S, Van Kerschaver E, Callaert K, Hens N, Van Damme P, Beutels P
Record ID 32010001404
Authors' objectives: Varicella zoster virus (VZV) is a DNA virus and a member of the herpes virus family. It is also known as human herpes virus type 3. Primary infection with VZV results in varicella, which is commonly known as chickenpox (CP), and mainly occurs in childhood. Following primary VZV infection, the virus migrates to the dorsal root or cranial sensory ganglia and remains there in a latent state. However, VZV may reactivate at a later stage in life, resulting in herpes zoster (HZ), which is commonly known as shingles.
Project Status: Completed
Year Published: 2010
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Belgium
MeSH Terms
  • Adult
  • Aged
  • Chickenpox Vaccine
  • Child
  • Vaccines, Attenuated
Organisation Name: Belgian Health Care Knowledge Centre
Contact Address: Administrative Centre Botanique, Doorbuilding (10th floor), Boulevard du Jardin Botanique 55, B-1000 Brussels, Belgium tel: +32 2 287 33 88 fax: +32 2 287 33 85
Contact Name: info@kce.fgov.be
Contact Email: info@kce.fgov.be

Belgian Health Care Knowledge Centre (KCE)

This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.